HDAC9 and Miyoshi myopathy: Taken together, our results show that ACY1215 may enhance anti-MM activities of Len/Dex in combination BTZ due to its inhibitory activities against class-I and class-IIb HDAC, respectively, providing the preclinical rationale for RVD ACY1215 clinical trials to further improve patient outcome.